A randomized multicenter phase II study is being planned to compare the cetuximab and TPF combination with the M.D. Anderson Cancer Center induction regimen consisting of carboplatin, paclitaxel, and cetiuximab, Dr. Haddad said.
The study was supported by Bristol-Myers Squibb. Dr. Haddad disclosed receiving honoraria and research support from the company, and honoraria from Sanofi-Aventis and Imclone Systems.